Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T cell response to CD200+/- acute myeloid leukemia

ABSTRACT: T cell response to CD200+/- acute myeloid leukemia

PROVIDER: PRJNA724667 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14309800_1.fastq.gz	Fastqsanger.gz
	SRR14309800_2.fastq.gz	Fastqsanger.gz
	SRR14309801_1.fastq.gz	Fastqsanger.gz
	SRR14309801_2.fastq.gz	Fastqsanger.gz
	SRR14309802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

T cell response to CD200+/- acute myeloid leukemia

Project description:Purpose: Understanding immunosuppression in AML is critical . The goals of this study are to compare the transcriptomics of human CD3+ T cells from humanized mice exposed to CD200+/- AML. Methods: NSG mice were humanized with 10x10^6 healthy PBMCs prior to the introduction of CD200+ or CD200- OCI-AML3 cells. After 10 days, CD3+ T cells were isolated and RNA was sequenced. Results: T cells from mice with CD200+ AML were characterized by an enrichment of T cell activation pathways and a downregulation of numerous metabolic pathways, including OXPHOS and glycolysis. Conclusions: Our results demonstrate, for the first time, that CD200+ AML can directly impair T cell metbolism.

2021-04-24 | GSE173194 | GEO

CD200 expression marks leukemia stem cells (LSC) in human AML part 2

Project description:The leukemia stem cell (LSC) populations of acute myeloid leukemia (AML) exhibit phenotypic, genetic and functional heterogeneity that contribute to therapy failure and relapse. Progress towards understanding the mechanistic basis for therapy resistance in LSCs has been hampered by difficulties in isolating cell fractions that enrich for the entire heterogeneous population of LSCs within individual AML samples. We previously reported that CD200 gene expression is upregulated in LSC-containing AML fractions. We demonstrate that CD200 is present on a greater proportion of CD45dim blasts compared to more differentiated CD45high cells in AML patient samples. In 75% of AML cases examined, CD200 was expressed on 10% of CD45dim blasts; of these, CD200 identified LSCs within the blast population in 90% of samples tested in xenotransplantation assays. Notably, CD200 expression captured both CD34- and CD34- LSCs within individual AML samples. Highly purified CD45dimCD200+ LSC-containing blasts were enriched in primitive HSC/progenitor-like signatures, while CD45dimCD200- nonengrafting blasts were enriched in myeloid-like signature. Moreover, analysis of CD45dimCD200+ blasts from NPM1-mutated AMLs also demonstrated an enrichment of primitive gene expression signatures compared to unfractionated (bulk) cells.

2020-10-10 | GSE159321 | GEO

CD200 expression marks leukemia stem cell (LSC) in human AML part 3

2020-10-10 | GSE159322 | GEO

CD200 expression marks leukemia stem cell (LSC) in human AML part 1

2020-10-10 | GSE159319 | GEO

Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia

Project description:Label-free quantitation dataset from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.

2022-03-09 | MSV000089029 | MassIVE

Drug-resistant acute myeloid leukemia

Project description:Drug-resistant acute myeloid leukemia

| PRJNA828404 | ENA

Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia

Project description:A deep-scale proteome and phosphoproteome database from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.

2022-03-07 | MSV000089012 | MassIVE

Stabilizing the Proteomes of Acute Myeloid Leukemia Cells: Implications for Cancer Proteomics

Project description:Data dependent analysis of acute myeloid leukemia samples in the presence and absence of the serine protease inhibitor DFP

2023-07-26 | MSV000092526 | MassIVE

lncRNA dependencies in acute myeloid leukemia

Project description:lncRNA dependencies in acute myeloid leukemia

| PRJNA354371 | ENA

Acute Myeloid Leukemia (AML) patient xenografts

Project description:Acute Myeloid Leukemia (AML) patient xenografts

| PRJNA736604 | ENA